Imaging dye tested to guide surgery for throat cancer
Tests a light-up dye to help surgeons see laryngeal and hypopharyngeal cancer during surgery.
Plain-language title generated from the registry record
Registry title: Fluorescence-guided Surgery in Laryngeal- and Hypopharyngeal Cancer: a Feasibility Trial
Key facts
- Where
- Rotterdam, NetherlandsSee the site
- Phase
- Phase 2
Where in Netherlands
- Erasmus Medical CenterRotterdam, NetherlandsNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Erasmus Medical Center
- Trial code
- NCT05752149
- Record updated
- 14 September 2026
- Original description
This is an open-label, single-dose, prospective clinical trial. The study comprises 2 work packages. The main objective of work package I (WP-1) is to assess feasibility of Fluorescence imaing (FLI) during total laryngectomy (TLE) and to assess the optimal dose of the cRGD-ZW800-1. Work package II (WP-II) is designed to assess whether FLI can detect and decrease tumor positive margins after a TLE.Read full original descriptionShow less
The STELLAR Trial: Fluorescence-guided Surgery in Laryngeal- and Hypopharyngeal Cancer: a Feasibility Trial
This is an open-label, single-dose, prospective clinical trial. The study comprises 2 work packages. The main objective of work package I (WP-1) is to assess feasibility of Fluorescence imaing (FLI) during total laryngectomy (TLE) and to assess the optimal dose of the cRGD-ZW800-1. Work package II (WP-II) is designed to assess whether FLI can detect and decrease tumor positive margins after a TLE.
Inclusion: Patients with biopsy-proven squamous cell Laryngeal and hypopharyngeal cancer, eligible for surgical resection of the tumor by TLE; ≥ 18 years of age; Written informed consent must be obtained; Sufficient knowledge of the Dutch language to understand the informed consent form.
Exclusion: Patients with previous kidney transplantation or a solitary functioning kidney; Patients using medications that may significantly impair renal function (i.e. NSAIDs, particularly COX-2 inhibitors), that cannot be paused during the course of the study; Immuno-compromised patients who do not have the ability to respond normally to an infection due to an impaired or weakened immune system, caused by either a preexisting disease or concomitant medications; History of a clinically significant allergy or anaphylactic reactions to any of the components of the agent; Other synchronous biopsy proven malignancies currently active, except for adequately treated in situ carcinoma of cervix and basal, squamous cell skin carcinoma, or other head- and neck squamous cell cancer; Patients with renal insufficiency (defined as eGFR < 60); Patients with measured QTc of 500 ms or higher at screening; Patients with laboratory abnormalities defined as:; Aspartate AminoTransferase, Alanine AminoTransferase, Gamma Glutamyl Transferase) or Alkaline Phosphatase levels above 5 times the ULN or; Total bilirubin above 3 times the ULN or; Platelet count below 100 x 109/L or; Hemoglobin below 4 mmol/L (females) or below 5 mmol/l (males); Patients pregnant or breastfeeding; Patients with ASA classification of 4 or higher.